Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology
- 1 February 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (2) , 375-386
Abstract
Background: Untargeted plasma metabolomic profiling combined with machine learning (ML) may lead to discovery of metabolic profiles that inform our understanding of pediatric CKD causes. We sought to identify metabolomic signatures in pediatric CKD based on diagnosis: FSGS, obstructive uropathy (OU), aplasia/dysplasia/hypoplasia (A/D/H), and reflux nephropathy (RN). Methods: Untargeted metabolomic quantification (GC-MS/LC-MS, Metabolon) was performed on plasma from 702 Chronic Kidney Disease in Children study participants (n: FSGS=63, OU=122, A/D/H=109, and RN=86). Lasso regression was used for feature selection, adjusting for clinical covariates. Four methods were then applied to stratify significance: logistic regression, support vector machine, random forest, and extreme gradient boosting. ML training was performed on 80% total cohort subsets and validated on 20% holdout subsets. Important features were selected based on being significant in at least two of the four modeling approaches. We additionally performed pathway enrichment analysis to identify metabolic subpathways associated with CKD cause. Results: ML models were evaluated on holdout subsets with receiver-operator and precision-recall area-under-the-curve, F1 score, and Matthews correlation coefficient. ML models outperformed no-skill prediction. Metabolomic profiles were identified based on cause. FSGS was associated with the sphingomyelin-ceramide axis. FSGS was also associated with individual plasmalogen metabolites and the subpathway. OU was associated with gut microbiome–derived histidine metabolites. Conclusion: ML models identified metabolomic signatures based on CKD cause. Using ML techniques in conjunction with traditional biostatistics, we demonstrated that sphingomyelin-ceramide and plasmalogen dysmetabolism are associated with FSGS and that gut microbiome–derived histidine metabolites are associated with OU.Keywords
Funding Information
- Foundation for the National Institutes of Health (U01DK106982)
- National Institute of Diabetes and Digestive and Kidney Diseases (P50DK114786)
This publication has 57 references indexed in Scilit:
- Epidemiology of chronic kidney disease in childrenPediatric Nephrology, 2011
- Rituximab Targets Podocytes in Recurrent Focal Segmental GlomerulosclerosisScience Translational Medicine, 2011
- Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's diseaseLipids in Health and Disease, 2011
- In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursorLipids in Health and Disease, 2011
- Organization of GC/MS and LC/MS metabolomics data into chemical librariesJournal of Cheminformatics, 2010
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Design and Methods of the Chronic Kidney Disease in Children (CKiD) Prospective Cohort StudyClinical Journal of the American Society of Nephrology, 2006
- Role for Matrix Metalloproteinase-2 in Oxidized Low-Density Lipoprotein–Induced Activation of the Sphingomyelin/Ceramide Pathway and Smooth Muscle Cell ProliferationCirculation, 2004
- Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapyNephrology Dialysis Transplantation, 2004
- Enzymes of Sphingolipid Metabolism: From Modular to Integrative SignalingBiochemistry, 2001